About This Fund
Columbus Life Science Fund II (FCR) is a Spanish venture capital fund managed by Columbus Venture Partners SGEIC, S.A., a specialist life sciences VC firm headquartered at Ronda Guglielmo Marconi 8, Paterna (Valencia, Spain). The fund was registered with the Spanish Comision Nacional del Mercado de Valores (CNMV) under registration number 244 in February 2019, with a target capitalization of approximately EUR 70 million, and constitutes the second flagship fund in Columbus Venture Partners' life sciences fund family following Columbus Innvierte Life Science I (2016 vintage). It focuses exclusively on early-stage biotechnology and pharmaceutical innovation, targeting portfolio companies capable of advancing novel therapeutic or industrial biotech products toward clinical or commercial milestones.
Columbus Life Science Fund II applies Columbus Venture Partners' distinctive investment model of combining therapeutic seed funding with hands-on infrastructure creation, working directly alongside early-stage founders to build the operational, regulatory, and manufacturing capabilities required to progress life sciences companies through their development stages. The fund typically leads seed-stage and early rounds in Spanish life sciences companies, providing not only capital but deep domain expertise across drug development, biologics, gene therapy, and biotech-enabled industrial applications. Its investment period ran from 2019 to 2021, during which the fund built a portfolio of nine companies operating across Spain's growing biotechnology sector.
The fund reflects Columbus Venture Partners' proven model of specialization within Spanish life sciences, a strategy that has generated a strong track record of exits including AskBio, Aura Biosciences, Algenex, Viralgen, and Sanifit Therapeutics across its fund family. Columbus Life Science Fund II was followed by Columbus Life Sciences Fund III (2021, EUR 120 million) and Columbus Life Sciences Fund IV (2023, EUR 150 million), each successive fund raising at a significantly higher size, validating the manager's ability to deliver returns and build institutional LP confidence across successive fund cycles. Columbus Venture Partners is registered with the CNMV as fund manager under registration number 107.